Clinical Trials on Fatty Liver in Hong Kong

Total 459 results

Matrix Pharmaceutical

Unknown

Chemotherapy in Treating Patients With Liver Cancer

Liver Cancer

United States, Hong Kong
Bukwang Pharmaceutical

Completed

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Hepatitis B

Hong Kong
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Cancer | Advanced Hepatocellular Carcinoma

Korea, Republic of, Hong Kong
GlaxoSmithKline

Completed

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Carcinoma, Hepatocellular

Taiwan, United States, Hong Kong
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (TRACER)

Hepatocellular Carcinoma

Hong Kong, Taiwan, Thailand
SCG Cell Therapy Pte. Ltd.

Recruiting

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (TCR-T)

Hepatocellular Carcinoma Recurrent | Hepatitis B Virus Related Hepatocellular Carcinoma

United States, Singapore, Hong Kong
Light Sciences Oncology

Completed

Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular | Liver Neoplasms

Taiwan, Hong Kong, Singapore
Novartis
Novartis Pharmaceuticals

Completed

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Hepatitis B

Hong Kong, Singapore, New Zealand
LG Life Sciences

Unknown

Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B (LB80380)

Chronic Hepatitis B

China, Korea, Republic of
Galvanize Therapeutics, Inc.

Terminated

A Clinical Evaluation of the Aliya™ System in Late Stage Cancer (INCITE LS)

Cancer of Lung, Kidney or Liver

Hong Kong, Spain, Netherlands
FibroGen

Terminated

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Liver Fibrosis Due to Chronic Hepatitis B Infection

Hong Kong, Thailand
Southern California Institute for Research and...

Recruiting

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

Non-Alcoholic Fatty Liver Disease | Non Insulin Dependent Diabetes | ALT

United States
LG Life Sciences

Completed

Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of
PharmaKing

Completed

Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

Non-alcholic Fatty Liver Disease

Korea, Republic of
PharmaKing

Completed

Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease (PMK-N01GI1)

Non-alcoholic Fatty Liver Disease

Korea, Republic of
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...

Recruiting

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)

Chronic Hepatitis C Infection

China, Japan
Hoffmann-La Roche

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

Hong Kong, Taiwan, New Zealand
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Hong Kong, China
Andreas Benesic, MD
MetaHeps GmbH

Unknown

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Adverse Reaction to Drug | Drug-induced Disorder of Liver

Hong Kong, Australia, Germany, Japan, Korea, Republic of
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong
Yungjin Pharm. Co., Ltd.

Terminated

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Nonalcoholic Fatty Liver Disease

Korea, Republic of
Gilead Sciences
F-star Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Korea, Republic of, Hong Kong
GlaxoSmithKline
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Hepatitis B | Chronic Hepatitis B Atypical

Korea, Republic of, Hong Kong
PharmaNest, Inc
Icahn School of Medicine at Mount Sinai; Chinese University of Hong Kong; Imperial... and other collaborators

Not yet recruiting

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-1)

Metabolic Dysfunction-associated Steatotic Liver Disease

United States, Hong Kong, United Kingdom, Spain
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enyo Pharma

Completed

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Taiwan
National Medical Research Council (NMRC), Singapore

Completed

Tamoxifen in Treating Patients With Primary Liver Cancer

Liver Cancer

New Zealand, Hong Kong, Indonesia, Malaysia, Pakistan, Singapore
Gilead Sciences

Completed

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Canada, United States, Hong Kong, United Kingdom, Switzerland, New Zealand
Arrowhead Pharmaceuticals

Terminated

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Hepatitis B

Korea, Republic of, Germany, China
Progen Pharmaceuticals

Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma (PATHWAY)

Cancer | Hepatocellular Carcinoma | Primary Liver Cancer | Liver Cancer | Hepatoma

Hong Kong, Singapore, United States, Australia, Canada, Italy, Malaysia, Spain, Taiwan, Thailand
Pfizer

Terminated

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

Hepatitis C, Chronic

Taiwan, Singapore, India, Korea, Republic of, Hong Kong
Novartis
Novartis Pharmaceuticals

Completed

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

Hepatitis B

Canada, France, United States, China
Cook Research Incorporated

Completed

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Liver Diseases | Liver Cirrhosis | Hypertension, Portal

United States, Australia, Hong Kong
Novartis Pharmaceuticals

Terminated

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma With c-MET Dysregulation

China, Hong Kong, Thailand, Singapore
Ligand Pharmaceuticals

Completed

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Hong Kong, Taiwan
AstraZeneca
Ionis Pharmaceuticals, Inc.

Completed

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma Metastatic

Korea, Republic of, Taiwan, Hong Kong, Japan
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany, Australia, Hong Kong, Switzerland, Spain, France, United States
Hoffmann-La Roche

Completed

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Hong Kong, Taiwan, Singapore
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
SuperSonic Imagine
Johann Wolfgang Goethe University Hospital

Completed

Liver Fibrosis Assessment With ShearWave Elastography

Liver Fibrosis

Denmark, France, Germany, Belgium, China, Greece, Hong Kong, Italy, Romania
Boston Scientific Corporation

Recruiting

SpyGlass Surgical Study

Pancreatic Diseases | Bile Duct Diseases | Hepatic Disease

United States, India, China, Hong Kong
Hoffmann-La Roche

Completed

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Carcinoma, Hepatocellular | Liver Metastases | Biliary Tract Cancer | Secondary Liver Cancer

Korea, Republic of, Denmark, Spain, Taiwan, United States, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, Nonalcoholic

Canada, United States, Puerto Rico, Japan, Korea, Republic of, Taiwan, Spain, Israel, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey, Colo...
LG Life Sciences

Completed

Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, China
Tobira Therapeutics, Inc.

Terminated

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Liver Cirrhosis | Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Australia, France, Germany, Spain, Poland, United Kingdom, Italy, Puerto Rico, Belgium, Hong Kong
Novartis Pharmaceuticals

Completed

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Hong Kong, Taiwan, Korea, Republic of
PowderMed

Completed

Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection

Chronic Hepatitis B

Thailand, Hong Kong, Singapore, Taiwan
Triangle Pharmaceuticals

Unknown

A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

Hepatitis B

United States, Canada, China, France, Singapore
Galmed Research and Development, Ltd.
Medical University of Graz; Tel-Aviv Sourasky Medical Center; Fondazione IRCCS... and other collaborators

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (Aramchol_005)

Liver Diseases | Fatty Liver | Non-Alcoholic Steatohepatitis | Liver Fibroses

United States, Chile, Israel, Italy, France, Germany, Mexico, Georgia, Lithuania, Hong Kong, Romania
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Terminated

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection (PATRON)

Cancer | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, Taiwan, Hong Kong, China

Clinical Trials on Fatty Liver in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations